- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Immuneering Corp (IMRX)
Immuneering Corp stock price live, this page displays NASDAQ IMRX stock exchange data. View the IMRX premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Immuneering Corp real time stock price chart below.
What Is the Immuneering Corp Stock Price Today?
The Immuneering Corp stock price today is 3.760.
What Is the Stock Symbol for Immuneering Corp?
The stock ticker symbol for Immuneering Corp is IMRX.
Is IMRX the Same as $IMRX?
$IMRX is a common way to refer to the Immuneering Corp ticker symbol in social media, forums, and online discussions. The dollar sign is a shorthand convention used to indicate that it is a stock ticker symbol
What Stock Exchange Does Immuneering Corp Trade On?
Immuneering Corp is listed and trades on the NASDAQ stock exchange.
Is Immuneering Corp a Good Stock to Buy?
Determining whether Immuneering Corp—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess the current Immuneering Corp share price compared with the fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the IMRX quote. (ISIN: US45254E1073)
What Is the Immuneering Corp Stock Price Today?
The Immuneering Corp stock price today is 3.760.
What Is the Stock Symbol for Immuneering Corp?
The stock ticker symbol for Immuneering Corp is IMRX.
Is IMRX the Same as $IMRX?
$IMRX is a common way to refer to the Immuneering Corp ticker symbol in social media, forums, and online discussions. The dollar sign is a shorthand convention used to indicate that it is a stock ticker symbol
What Stock Exchange Does Immuneering Corp Trade On?
Immuneering Corp is listed and trades on the NASDAQ stock exchange.
Is Immuneering Corp a Good Stock to Buy?
Determining whether Immuneering Corp—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess the current Immuneering Corp share price compared with the fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the IMRX quote. (ISIN: US45254E1073)
3.760
+0.100(+2.73%)
Real-time Data·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
3.670
3.841
52 wk Range
3.380
8.480
IMRX is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
3.6703.841
52 wk Range
3.3808.480
Key Statistics
Edit
Prev. Close
Open
Volume
Average Vol. (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Vol. (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
IMRX Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Analysts Sentiment
Strong Buy
Price Target
17.167
Upside
+356.56%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Quickly burning through cash
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Buy
Technical Indicators
Strong Buy
Moving Averages
Neutral
Analyst Ratings
7 Buy
0 Hold
0 Sell
Ratings:
7 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 17.167
(+356.56% Upside)
Immuneering Corp Earnings Call Summary for Q3/2025
- Immuneering's cash reserves surged to $227.6 million, extending operational runway into 2029 following $225 million in fundraising through private placements and stock offerings.
- Tevid MetNib's phase 2A trial for pancreatic cancer shows promising outcomes, with survival data exceeding current standards and a 'remarkable' complete response noted by CEO Ben Zeskind.
- The company plans to initiate a phase 3 trial for Tevid MetNib in mid-2026, with regulatory feedback expected in Q4 2025 and updated survival data in H1 2026.
- Patent exclusivity for Tevid MetNib secured until 2042, with exploration of combination trials with pharmaceutical partners including Eli Lilly and Regeneron.
- Stock closed at $6.74 (down 2.23%), with a slight 1.04% increase to $6.81 in aftermarket trading as the company positions itself as a unique player in its pathway.
Last Updated: 11/12/2025, 05:34 PM
Read Full TranscriptEarnings
Latest Release
Aug 05, 2026
EPS / Forecast
-0.27 / -0.27
Revenue / Forecast
-- / --
Compare IMRX to Peers and Sector
Metrics to compare | IMRX | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipIMRXPeersSector | |
|---|---|---|---|---|
P/E Ratio | −4.3x | −1.8x | −0.3x | |
PEG Ratio | −0.09 | −0.02 | 0.00 | |
Price / Book | 1.3x | 2.8x | 2.6x | |
Price / LTM Sales | - | 26.6x | 2.9x | |
Upside (Analyst Target) | 369.0% | 119.6% | 62.0% | |
Fair Value Upside | Unlock | 8.4% | 9.5% | Unlock |
Immuneering Corporation, a late-stage oncology company, develops medicines for broad populations of cancer patients in the United States. The company develops IMM-1-104 (atebimetinib), a dual-MEK inhibitor that is in a Phase 3 clinical trial to treat patients with cancer, including pancreatic and non-small cell lung cancer caused by mutations of RAS or RAF; IMM-6-415 (envometinib), which is in Phase 1/2a clinical trial for the treatment of patients with solid tumors; and multiple deep cyclic inhibitor discovery programs. The company has clinical supply agreements with Regeneron Pharmaceuticals to evaluate atebimetinib in combination with Libtayo in patients with unresectable or metastatic RAS-mutant non-small cell lung cancer; and with Eli Lilly and Company to evaluate atebimetinib in combination with olomorasib in patients with advanced or metastatic KRAS G12C-mutant non-small cell lung cancer. Immuneering Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.
Ownership
Ownership Overview
Top Holders
People Also Watch
FAQ
What Is the Immuneering (IMRX) Stock Price Today?
The Immuneering stock price today is 3.760 USD.
What Stock Exchange Does Immuneering Trade On?
Immuneering is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for Immuneering?
The stock symbol for Immuneering is "IMRX."
What Is the Immuneering Market Cap?
As of today, Immuneering market cap is 243.590M USD.
What Is Immuneering's Earnings Per Share (TTM)?
The Immuneering EPS (TTM) is -0.98.
When Is the Next Immuneering Earnings Date?
Immuneering will release its next earnings report on Nov 05, 2026.
From a Technical Analysis Perspective, Is IMRX a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
How Many Times Has Immuneering Stock Split?
Immuneering has split 0 times.
How Many Employees Does Immuneering Have?
Immuneering has 57 employees.
What is the current trading status of Immuneering (IMRX)?
As of Oct 20, 2026, Immuneering (IMRX) is trading at a price of 3.760 USD, with a previous close of 3.660 USD. The stock has fluctuated within a day range of 3.670 USD to 3.841 USD, while its 52-week range spans from 3.380 USD to 8.480 USD.
What Is Immuneering (IMRX) Price Target According to Analysts?
The average 12-month price target for Immuneering is 17.167 USD, with a high estimate of 30 USD and a low estimate of 12 USD. 7 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +356.56% Upside potential.
What Is the IMRX Premarket Price?
IMRX's last pre-market stock price is 3.750 USD. The pre-market share volume is 1,200.000, and the stock has decreased by 0.090, or 2.460%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.